Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31722364 | 0.88 | SRD5A1 (0.47) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL1339630 | 0.88 | MAOA (0.48) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL12430503 | 0.88 | SRD5A1 (0.46) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL8599479 | 0.78 | CA1 (0.46) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL30067620 | 0.77 | ALDH1A1 (0.41) | SRD5A1CA9PTK2CES1KMT2A | |
| SCHEMBL5543767 | 0.76 | CES1 (0.38) | SRD5A1PTK2CES1CYP2A6ABCB1 | |
| SCHEMBL1339854 | 0.74 | TDP2 (0.47) | SRD5A1PTK2CES1CYP2A6ABCB1 | |
| SCHEMBL569106 | 0.74 | TYMS (0.44) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL1150797 | 0.74 | KDM4E (0.38) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL1340784 | 0.74 | MEN1 (0.45) | SRD5A1CES1CYP2A6ABCB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4729508-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12583856-B2 | Inhibitors of protein kinase A | BLUEPRINT MEDICINES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| CN-118684628-B | Substituted indanyl imidazole compound, preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2025-06-17 | — | — | CN | disclosed |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-20250109126-A1 | DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS | AC IMMUNE SA (CH) | 2025-04-03 | — | — | US | disclosed |
| CN-119118872-A | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4452972-A1 | DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS | AC Immune SA (CH) | 2024-10-30 | — | — | EP | disclosed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | disclosed |
| CN-101379061-A | E1 activating enzyme inhibitor | MILLENNIUM PHARM INC (US) | 2009-03-04 | — | — | CN | disclosed |
| EP-1989206-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2008071765-A1 | PHARMACEUTICALLY ACTIVE SPIRO-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NYCOMED GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | NAGOYA INDUSTRIAL SCIENCE RESEARCH CENTER (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007092213-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1741693-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | Nagoya Industrial Science Research Institute (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | ADH1C, ADH1A, ADH5 | SRD5A1 19/4885CA1 4211/4885CA2 4052/4885 |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | SRD5A1 2557/4885CA1 1756/4885CA2 813/4885 |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | SRD5A1 3364/4885CA1 3816/4885CA2 2770/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | SRD5A1 2654/4885CA1 4628/4885CA2 4262/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | SRD5A1 2149/4885CA1 3114/4885CA2 1313/4885 |
| US-12583856-B2 | Inhibitors of protein kinase A | CSNK1A1, CSNK1A1L, CSNK1G1 | SRD5A1 364/4885CA1 2706/4885CA2 897/4885 |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | SRD5A1 702/4885CA1 4593/4885CA2 3165/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | SRD5A1 1775/4885CA1 3091/4885CA2 1431/4885 |
| US-20250109126-A1 | DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS | NLRP3, NLRP1, NOD1 | SRD5A1 774/4885CA1 4146/4885CA2 3785/4885 |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | SRD5A1 1866/4885CA1 3884/4885CA2 2190/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | SRD5A1 744/4885CA1 2434/4885CA2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.